Biocytogen and Nanjing Chia Tai Tianqing Announce IND Approval in China for Co-Developed Anti-IGF-1R Antibody NTB003 (BCG009)

Contributed by: Business Wire

Logo

Tags

Health

Clinical Trials

Research

Science

Pharmaceutical

Optical

Biotechnology

NJCTTQ, NTB003, IND approval

More Like This

Biocytogen Enters into Multi-Target Antibody Agreement with Neurocrine Biosciences

Biocytogen Enters Into Evaluation and Potential Licensing Agreement With BioCopy For TCR-mimic Antibodies

Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement

(Graphic: Business Wire)

Biocytogen Launches RenBiologics, A Sub-Brand Focused on Out-Licensing Fully Human Antibodies For Therapeutic Development

Biocytogen/Eucure Biopharma to Present Complete Clinical Data from YH003 (anti-CD40 mAb) Phase I Trial at ESMO 2023

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates

Biocytogen Secures Japan Patent for RenMab Platform, Expands Global Patent Portfolio for RenMice Fully Human Antibody/TCR Platform

Biocytogen Enters into Bispecific Antibody Drug Conjugate Agreement with Radiance Biopharma